Evidence map›Paper›PMID 35613883›Full record

ArticleRNA (New York, N.Y.)2022

Antisense modulation of IL7R splicing to control sIL7R expression in human CD4

Gaddiel Galarza-Muñoz, Debbie Kennedy-Boone, Geraldine Schott, Shelton S Bradrick, Mariano A Garcia-Blanco

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Expansion of Splice-Switching Therapy with Antisense Oligonucleotides.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gaddiel Galarza-MuñozAutoimmunity BioSolutions, Galveston, Texas 77550, USA.
Debbie Kennedy-BooneDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77550, USA.
Geraldine SchottDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77550, USA.
Shelton S BradrickDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77550, USA.
Mariano A Garcia-BlancoAutoimmunity BioSolutions, Galveston, Texas 77550, USA.
The University of Texas Medical Branch at Galveston · USEmergent BioSolutions (United States) · US

Funding

Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cellsR41AI149920 · NIAID · AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. · PI GALARZA-MUNOZ, GADDIEL · 2020 to 2020
$284k
Development of a novel accurate therapy for Multiple SclerosisR41AI141323 · NIAID · AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. · PI GALARZA-MUNOZ, GADDIEL · 2019 to 2019
$225k
Novel accurate therapy for Multiple Sclerosis: Optimization of antisense oligonucleotides delivery and functionality in primary T cellsR43AI143319 · NIAID · AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC. · PI GALARZA-MUNOZ, GADDIEL · 2019 to 2019
$170k
NIAID NIH HHS R41 AI141323NIAID NIH HHS R41 AI149920NIAID NIH HHS R43 AI143319
6 · The paper itself

Abstract

The interleukin 7 receptor (

Indexed as

CD4-Positive T-LymphocytesMultiple SclerosisReceptors, Interleukin-7AnimalsExonsHumansInterleukin-7 Receptor alpha SubunitMiceOligonucleotides, AntisenseRNA SplicingT-LymphocytesIL7R protein, humanInterleukin-7 Receptor alpha SubunitOligonucleotides, AntisenseReceptors, Interleukin-7antisense oligonucleotidesIL7Rimmuno-oncologymultiple sclerosissplicingT cells

Identifiers

PMID35613883
PMCPMC9297843
OpenAlexW4281561083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.